Volume 4, issue 2, June 2020
18 articles in this issue
-
-
-
-
Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review
Authors (first, second and last of 5)
-
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
Authors (first, second and last of 13)
-
Cost of Delivering Secondary Healthcare Through the Public Sector in India
Authors (first, second and last of 6)
-
-
Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
Authors (first, second and last of 6)
-
Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines
Authors (first, second and last of 5)
-
-
Ticagrelor Removal by CytoSorb® in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis
Authors (first, second and last of 11)
-
Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands
Authors (first, second and last of 4)
-
Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India
Authors (first, second and last of 8)
-
Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection
Authors (first, second and last of 8)
-
-
A Nationwide Study of Prevalence Rates and Characteristics of 199 Chronic Conditions in Denmark
Authors (first, second and last of 4)
-
Treatment Patterns and Costs Associated with Stage IV Non-Small Cell Lung Cancer in a Mexican Population: A Chart Review
Authors (first, second and last of 6)
-
Out-of-Pocket Cancer Care Costs and Value Frameworks: A Case Study in a Community Oncology Practice with a Financial Navigator Program
Authors (first, second and last of 5)
